%20(1)_edited.jpg)
%201%20(1).png)
Your content has been submitted
Your content has been submitted
Your content has been submitted
An error occurred. Try again later
Your content has been submitted
An error occurred. Try again later
Your content has been submitted
An error occurred. Try again later
An error occurred. Try again later
An error occurred. Try again later
Your content has been submitted
Your content has been submitted
Your content has been submitted
Your content has been submitted
Your content has been submitted
Your content has been submitted
Your content has been submitted
Your content has been submitted
An error occurred. Try again later
An error occurred. Try again later
Your content has been submitted
Your content has been submitted
Your content has been submitted
30
Countries
including the US FDA, have already approved cannabinoid-based drugs for treatment of MS-related Spasticity & rare forms of epilepsy
$800
Million
of revenue generated in 2022 for approved cannabinoid-based medicines
but existing approved cannabinoid medicines are sub-optimal due to poor oral absorption.
.png)
Elixie has developed a high-absorption drug-delivery technology called NANOLIX, which has been clinically proven to promote the fast, efficient and consistent absorption of cannabinoids and maximize efficacy.
Instant Relief
Quicker onset of action : 4x faster
Bioavailability
Higher rate of efficacy
at a small dose
Consistent Absorption
Predictable and repetitive effect relief for spasticity sufferers
Self Nano Emulsifying Drug Delivery System (SNEDDS) for Oral Drugs
NANOLIX encapsulates cannabinoids in nanoemulsions and is used as a platform to enhance and expand existing API’s, creating cannabinoid 'super drugs' for rapid relief.
NANOLIX Patented
Technology
EU - Granted
US | Canada | Pending
01
.png)
NANOLIX pre-concentrated composition of cannabinoids and Pro-Nano liposphere formulation.
02
.png)
In contact with water, NANOLIX spheres spontaneously formed around the cannabinoids.
03
.png)
The cannabinoids are encapsulated in NANOLIX nanoparticles.
Clinically validated and published in 6 peer reviewed publications
Key International Research and Clinical Collaborators
.png)
Elixie Products
%206%20(1).png)
We enhance clinically proven API’s with our Nanolix Technology to create highly soluble and affective cannabinoid-based medicines. We have two medicines in development, Elidiol,targets rare forms of Epilepsy. Our second product Elinol, targets a “rare” neurodegenerative disease. Both Elidiol and Elinol are eligible for FDA orphan disease designation.
————— Elidiol®
—————Elinol®
.png)
%205%20(1).png)
Elidiol
NANOLIX & Cannabidiol (Purified CBD)
Elidiol Oral emulsion is created by combining NANOLIX with Cannabidiol (Purified CBD) to accelerate drug absorption and provide rapid symptomatic relief for rare epilepsy.
The successful in-human pharmacokinetic and safety studies formed the foundation for advancing to Phase 1 clinical trials and seeking FDA marketing approval.
Elinol
NANOLIX & Cannabinoids (THC + CBD)
Elinol Oral emulsion is created through a combination of NANOLIX with Tetrahydrocannabinol (THC) and Cannabidiol (CBD) to accelerate drug absorption and provide rapid relief from spasticity for patients suffering from neurodegenerative diseases such as multiple sclerosis (MS).
The successful in-human pharmacokinetic and safety studies formed the foundation for advancing to Phase 1 clinical trials and seeking FDA marketing approval.
Product Development Pipeline
%206.png)
Drug Candidate
Pre-Clinical
Phase 0
Phase 1
Phase 2/3
Marketing
Approval
Elidiol®
NANOLIX® + Cannabidiol
(Purified CBD)
Elinol is eligible for FDA orphan disease designation.
Anticonvulsant medication
Elinol is eligible for FDA orphan disease designation.
Elinol®
NANOLIX® + Cannabinoids
(THC + CBD)
Elinol is eligible for FDA orphan disease designation.
Spasticity relief drug
Elinol is eligible for FDA orphan disease designation.
%207%20(2).png)
%202%20(1).png)
Elixie was founded in 2019 with its headquarters located in Tel Aviv, Israel. Our deep commitment lies in addressing the pressing healthcare challenges faced by millions of individuals living with chronic conditions.
Elixie is powered by a dedicated team of passionate visionaries who bring together diverse expertise and unwavering commitment. We share a common belief in the transformative power of science, and our relentless pursuit of excellence propels us to explore uncharted territories in nanotechnology, pushing the boundaries to provide innovative solutions for relief.
%20(5).png)
Join us in driving nano-tech healthcare innovation
forward
%201%20(1).png)
Headquarters
No. 4 Ariel Sharon St., Givatayim, Israel
R&D lab:
Tarshish Industrial Park St 5, Caesarea, Israel
Created by Zenverse Studio
Your content has been submitted
2023 Elixie. All right reserved.